![]() |
Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cance
A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with...
More... |
| All times are GMT -7. The time now is 08:48 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021